C 28 H 37 N 3 O 2 , monoclinic, P21/c (no. 14), a = 11.0454 (4) 
Bruker programs [1] , SHELX [2, 3] The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.
Source of material
n-Dipropylamine (2.3 g, 0.023 mol) was added to a solution of 1-(chloroacetyl)-2,3-diphenyl-1,3-diazaspiro[4.5]decan-4-one (1.8 g, 0.0047 mol) in toluene (40 mL) and the reaction mixture was heated at 90°C for 20 h. After cooling to room temperature the solvent was removed under reduced pressure to give a residual oil which was dissolved in dichloromethane (100 mL). The organic phase was washed with water, dried (Na 2 SO4) and evaporated under vacuum to yield the title compound as a viscous oil. The crude oil was purified by column chromatography using silica gel as a stationary phase and a mixture of petroleum ether (40-60°C): ethyl acetate (7:3) as a mobile phase to give the title compound as a white [4] . The title compound was re-crystallized from ethyl acetate to afford colorless single crystals.
Experimental details
Carbon-bound hydrogen atoms were placed in calculated positions and were included in the refinement using the riding model approximation, with U iso (H) set to 1.2Ueq(C) and 1.5Ueq(Methyl).
Discussion
Epilepsy is a chronic disorder of the brain that affects approximately 50 million people, making it one of the most common neurological diseases worldwide [5] . Many new antiepileptic drugs have been introduced in the market, however the available antiepileptics fail to prevent the seizures in approximately 30% of patients [6] . Moreover, these medications are associated with severe adverse effects such as gingival hyperplasia, megaloblastic anaemia and hepatotoxicity [7, 8] . Therefore, there is a great need for the development of new, more effective and less toxic antiepileptic agents. The title compound displayed 83% protection toward subcutaneous pentylenetetrazole -induced convulsions in mice at dose level 0.035 mmol/kg [3] .
In the crystal structure of the title compound, the asymmetric unit contains one independent molecule. Molecules form extended chains along the crystallographic c direc- 
